Español
India
Italiano
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Español
India
Italiano
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Artivion
(NYSE:AORT)
Intraday
$23.75
0.31
[1.32%]
After-Hours
$23.75
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$23.75
0.31
[1.32%]
At close: Jun 6
$23.75
0
[0.00%]
After Hours: 7:01PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Artivion Stock (NYSE:AORT)
Artivion Stock (NYSE: AORT)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, May 07, 2024
Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Avi Kapoor
Artivion shares are trading higher after the company reported a Q1 earnings beat and raised the bottom end of its FY24 guidance range.
Benzinga Newsdesk
Tempur Sealy Posts Upbeat Earnings, Joins FibroGen, Coca-Cola Consolidated, Fabrinet And Other Big Stocks Moving Higher On Tuesday
Avi Kapoor
Stifel Maintains Buy on Artivion, Raises Price Target to $25
Benzinga Newsdesk
Breaking Down Artivion: 4 Analysts Share Their Views
Benzinga Insights
Needham Maintains Buy on Artivion, Raises Price Target to $30
Benzinga Newsdesk
Monday, May 06, 2024
Artivion Revises FY24 Revenue Guidance From 8%-12% To 9%-12% Y/Y Growth On Constant Currency Basis
Benzinga Newsdesk
Artivion Q1 2024 Adj EPS $0.06 Beats $(0.11) Estimate, Sales $97.431M Beat $91.978M Estimate
Benzinga Newsdesk
Monday, April 29, 2024
Artivion To Present New Clinical Data For On-X Aortic Heart Valve And AMDS At 104th AATS Annual Meeting
Benzinga Newsdesk
Monday, April 08, 2024
Needham Maintains Buy on Artivion, Maintains $25 Price Target
Benzinga Newsdesk
Monday, February 19, 2024
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights
Friday, February 16, 2024
Why DoorDash Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Avi Kapoor
Applied Materials Posts Upbeat Earnings, Joins Texas Roadhouse, Vulcan Materials And Other Big Stocks Moving Higher On Friday
Avi Kapoor
Artivion shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY24 revenue guidance. Also, Needham maintained a Buy rating on the stock and raised its price target from $22 to $25.
Benzinga Newsdesk
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights
Needham Maintains Buy on Artivion, Raises Price Target to $25
Benzinga Newsdesk
Thursday, February 15, 2024
Artivion Sees FY24 Revenue $382M-$396M Vs $384.26M Est.
Benzinga Newsdesk
Artivion Q4 EPS $0.11 Beats $(0.10) Estimate, Sales $93.67M Beat $89.29M Estimate
Happy Mohamed
Earnings Scheduled For February 15, 2024
Benzinga Insights
Wednesday, February 14, 2024
Artivion's Earnings: A Preview
Benzinga Insights
Monday, January 29, 2024
Artivion Presents Data From AMDS PERSEVERE Trial A 60th Society Of Thoracic Surgery Annual Meeting
Benzinga Newsdesk
Thursday, December 28, 2023
'Most Suspicious Congressional Stock Trade?' Little-Known Med Tech Firm Surges 48% In Just 2 Months After Senator Tina Smith Bought The Dip
Navdeep Yadav
Thursday, December 07, 2023
Needham Reiterates Buy on Artivion, Maintains $22 Price Target
Benzinga Newsdesk
Wednesday, December 06, 2023
Artivion Also Reaffirmed Its FY23 Financial Guidance Provided On Nov. 2, 2023
Benzinga Newsdesk
Artivion Appoints Lance Berry As Executive Vice President, CFO Effective Dec. 4, 2023; Succeeds D. Ashley Lee Who Will Retire At End Of The Year
Benzinga Newsdesk
Tuesday, November 28, 2023
Forget Nancy Pelosi, This Democratic Senator Made Up To $55K Profit In Nearly 3 Weeks On This Medical Device Stock That's Lost 40% In Last 5 Years
Shanthi Rexaline
Tuesday, November 21, 2023
Why American Eagle Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin
Agilent Posts Upbeat Results, Joins Burlington Stores, Hibbett And Other Big Stocks Moving Higher On Tuesday
Lisa Levin
A Congress Member Bought Up To $200K In Artivion Stock: Here's What You Need To Know
Benzinga Insights
Why Symbotic Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
Lisa Levin
Friday, November 03, 2023
Needham Maintains Buy on Artivion, Lowers Price Target to $22
Benzinga Newsdesk
Thursday, November 02, 2023
Artivion Q3 2023 Adj EPS $0.02 Beats $(0.06) Estimate, Sales $87.85M Beat $84.32M Estimate
Benzinga Newsdesk
Earnings Scheduled For November 2, 2023
Benzinga Insights
Thursday, October 05, 2023
Artivion Announces Presentation Of Real World Data From Post Market Study Of On-X Aortic Heart Valve Replacement Patients Treated With Low Dose Warfarin
Benzinga Newsdesk
Artivion Announces Presentation Of Interim Data From AMDS PERSEVERE Trial At 37th European Association For Cardio-Thoracic Surgery Annual Meeting
Benzinga Newsdesk
Thursday, August 24, 2023
Watching Artivion; Hearing Zacks Home Run Investor Newsletter Picks Stock
Happy Mohamed
Thursday, August 10, 2023
Artivion VP Awarded $78K Worth of Stock Options
Benzinga Insights
Friday, August 04, 2023
Needham Reiterates Buy on Artivion, Maintains $26 Price Target
Benzinga Newsdesk
Thursday, August 03, 2023
Artivion Raises FY23 Revenues Forecast From $337M-$348M To $342M-$350M, Consensus $340.69M
Benzinga Newsdesk
Artivion Q2 Adj EPS $0.06 Beats $(0.08) Estimate, Sales $89.25M Beat $84.24M Estimate
Benzinga Newsdesk
Earnings Scheduled For August 3, 2023
Benzinga Insights
Wednesday, August 02, 2023
Earnings Preview: Artivion
Benzinga Insights
Tuesday, May 23, 2023
Artivion Secures FDA PMA Approval Of PerClot And Transfer Of PMA To Baxter
Benzinga Newsdesk
Artivion Announces FDA PMA Approval of PerClot and Transfer of PMA to Baxter
Benzinga Newsdesk
Monday, May 08, 2023
Morgan Stanley Maintains Equal-Weight on Artivion, Raises Price Target to $15
Benzinga Newsdesk
Friday, May 05, 2023
Artivion shares are trading higher after the company reported better-than-expected Q1 EPS and sales results. Also, Needham maintained a Buy rating on the stock and raised its price target from $23 to $26.
Benzinga Newsdesk
Needham Maintains Buy on Artivion, Raises Price Target to $26
Benzinga Newsdesk
Thursday, May 04, 2023
Artivion Q1 EPS $0.02 Beats $(0.12) Estimate, Sales $83.23M Beat $80.35M Estimate
Benzinga Newsdesk
Artivion: Q1 Earnings Insights
Benzinga Insights
Earnings Scheduled For May 4, 2023
Benzinga Insights
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch